Quest for the right Drug
דמוסטין 25 מ"ג DEMUSTIN 25 MG (BENDAMUSTINE HYDROCHLORIDE)
תרופה במרשם
תרופה בסל
נרקוטיקה
ציטוטוקסיקה
צורת מתן:
תוך-ורידי : I.V
צורת מינון:
אבקה להכנת תמיסה מרוכזת לעירוי : POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION
עלון לרופא
מינוניםPosology התוויות
Indications תופעות לוואי
Adverse reactions התוויות נגד
Contraindications אינטראקציות
Interactions מינון יתר
Overdose הריון/הנקה
Pregnancy & Lactation אוכלוסיות מיוחדות
Special populations תכונות פרמקולוגיות
Pharmacological properties מידע רוקחי
Pharmaceutical particulars אזהרת שימוש
Special Warning עלון לרופא
Physicians Leaflet
Adverse reactions : תופעות לוואי
4.8 Undesirable effects The most common adverse reactions with bendamustine hydrochloride are hematological adverse reactions (leukopenia, thrombopenia), dermatologic toxicities (allergic reactions), constitutional symptoms (fever), gastrointestinal symptoms (nausea, vomiting). The table below reflects the data obtained with bendamustine hydrochloride. Table 1: Adverse reactions in patients treated with bendamustine hydrochloride. MedDRA system Very common ≥1/10 Common Uncommon Rare Very rare Not known organ class ≥1/100 to <1/10 ≥1/1,000 to ≥1/10,000 to <1/10, 000 (cannot be <1/100 <1/1,000 estimated from the available data) Infections and Infection NOS Pneumocystis Sepsis Pneumonia infestations Including jirovecii primary Opportunistic pneumonia atypical infection (e.g. Herpes zoster, cytomegalovirus, hepatitis B) Neoplasma Tumour lysis Myelodysplastic syndrome, benign, malignant syndrome acute myeloid and unspecified leukemia (including cyst and polyp) Blood and Leukopenia NOS, Haemorrhage, Pancytopenia Bone marrow Haemolysis failure lymphatic system Thrombocytopenia Anaemia, disorders Lymphopenia Neutropenia Immune system Hypersensitivity Anaphylactic Anaphylactic disorders NOS reaction, shock Anaphylactoid reaction Nervous system Headache Insomnia Somnolence, Dysgeusia, disorders Dizziness Aphonia Paraesthesia, Peripheral sensory neuropathy, Anticholinergic syndrome, Neurological disorders, Ataxia, Encephalitis Cardiac disorders Cardiac Pericardial Tachycardia Atrial dysfunction, effusion, fibrillation such as Myocardial palpitations, infarction, angina pectoris, Cardiac failure Arrhythmia Vascular Hypotension, Acute circulatory Phlebitis disorders Hypertension failure Respiratory, Pulmonary Pulmonary Pneumonitis, thoracic and dysfunction fibrosis Pulmonary alveolar mediastinal haemorrhage disorders Gastrointestinal Nausea, Vomiting Diarrhoea, Haemorrhagic disorders Constipation, oesophagitis, Stomatitis Gastrointestinal haemorrhage Skin and Alopecia, Erythema, Stevens – subcutaneous Skin disorders Dermatitis, Pruritus, Johnson tissue disorders NOS Maculopapular syndrome, Urticaria rash, Toxic Hyperhidrosis Epidermal Necrolysis (TEN), Drug reaction with eosinophilia and systemic symptoms (DRESS)* Reproductive Amenorrhea Infertility system and breast disorders Hepatobiliary Hepatic disorder failure General disorders Mucosal Pain, Chills, Multi organ and inflammation, Dehydration, failure administration Fatigue, Pyrexia Anorexia site conditions Investigations Haemoglobin AST increase, ALT decrease, Creatinine increase, Alkaline increase, Urea increase phosphatase increase, Bilirubin increase, Hypokalemia Renal and urinary Renal failure disorders NOS= Not otherwise specified (*=combination therapy with rituximab) Description of selected adverse reactions There have been isolated reports of necrosis after accidental extra-vascular administration and tumour lysis syndrome, and anaphylaxis. The risk of myelodysplastic syndrome and acute myeloid leukaemias is increased in patients treated with alkylating agents (including bendamustine). The secondary malignancy may develop several years after chemotherapy has been discontinued. Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Any suspected adverse events should be reported to the Ministry of Health according to the National Regulation by using an online form http://forms.gov.il/globaldata/getsequence/getsequence.aspx?formType=AdversEffectMedic@moh.gov.il
שימוש לפי פנקס קופ''ח כללית 1994
לא צוין
תאריך הכללה מקורי בסל
לא צוין
הגבלות
לא צוין
מידע נוסף
עלון מידע לרופא
11.06.19 - עלון לרופאעלון מידע לצרכן
11.06.19 - עלון לצרכןלתרופה במאגר משרד הבריאות
דמוסטין 25 מ"ג